You are here: Welcome to the MPKB » Welcome to the MPKB » Science behind Marshall Paradigm » Science behind olmesartan (Benicar) » Safety of olmesartan (Benicar)
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revisionBoth sides next revision
home:protocol:olmesartan:safety [12.29.2018] – [Notes and comments] sallieqhome:protocol:olmesartan:safety [06.11.2019] – [Data supporting the safety of higher than typical dosing frequencies] sallieq
Line 35: Line 35:
  
 The [[http://www.benicar.com/pdf/prescribing_information.pdf|label for olmesartan]] states that the drug is well-tolerated. Adverse events were similar to those experienced by the placebo group – a group of patients who were not given the drug at all. Adverse events were generally “mild, transient and not related to dose.” The frequency of adverse events also had no relationship to the dose of olmesartan. The [[http://www.benicar.com/pdf/prescribing_information.pdf|label for olmesartan]] states that the drug is well-tolerated. Adverse events were similar to those experienced by the placebo group – a group of patients who were not given the drug at all. Adverse events were generally “mild, transient and not related to dose.” The frequency of adverse events also had no relationship to the dose of olmesartan.
 +
 +From a MPStudySite topic 
 +<blockquote>  a Member recently reported "taking a whole days worth of Benicar into my mouth and they were down before I could stop them.  Had forgotten I hadn't just put the one 6 a.m. dose in the container....  no adverse effects.</blockquote>
  
  
home/protocol/olmesartan/safety.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.